We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed at $53.19 in the latest trading session, marking a -1.85% move from the prior day. This change lagged the S&P 500's 0.79% loss on the day. Meanwhile, the Dow lost 0.53%, and the Nasdaq, a tech-heavy index, lost 0.46%.
Prior to today's trading, shares of the company had lost 10.28% over the past month. This has lagged the Medical sector's loss of 0.76% and the S&P 500's loss of 2.43% in that time.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. The company is expected to report EPS of -$1.91, down 26.49% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.67 million, up 949.63% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$7.69 per share and revenue of $119.24 million, which would represent changes of -263.62% and -86.97%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 5.8% lower. CRISPR Therapeutics AG is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 158, which puts it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know
CRISPR Therapeutics AG (CRSP - Free Report) closed at $53.19 in the latest trading session, marking a -1.85% move from the prior day. This change lagged the S&P 500's 0.79% loss on the day. Meanwhile, the Dow lost 0.53%, and the Nasdaq, a tech-heavy index, lost 0.46%.
Prior to today's trading, shares of the company had lost 10.28% over the past month. This has lagged the Medical sector's loss of 0.76% and the S&P 500's loss of 2.43% in that time.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. The company is expected to report EPS of -$1.91, down 26.49% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.67 million, up 949.63% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$7.69 per share and revenue of $119.24 million, which would represent changes of -263.62% and -86.97%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 5.8% lower. CRISPR Therapeutics AG is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 158, which puts it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.